Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Depreciation & Amortization (CF): 2020-2024

Historic Depreciation & Amortization (CF) for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to $113,000.

  • NewAmsterdam Pharma Co N.V's Depreciation & Amortization (CF) rose 128.57% to $64,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $212,000, marking a year-over-year increase of 182.67%. This contributed to the annual value of $113,000 for FY2024, which is 130.61% up from last year.
  • According to the latest figures from FY2024, NewAmsterdam Pharma Co N.V's Depreciation & Amortization (CF) is $113,000, which was up 130.61% from $49,000 recorded in FY2023.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Depreciation & Amortization (CF) ranged from a high of $113,000 in FY2024 and a low of $1,142 during FY2020.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median Depreciation & Amortization (CF) value was $49,000 (recorded in 2023), while the average stood at $57,000.
  • Data for NewAmsterdam Pharma Co N.V's Depreciation & Amortization (CF) shows a peak YoY skyrocketed of 444.44% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows NewAmsterdam Pharma Co N.V's Depreciation & Amortization (CF) stood at $1,142 in 2020, then spiked by 337.92% to $5,000 in 2021, then spiked by 80.00% to $9,000 in 2022, then skyrocketed by 444.44% to $49,000 in 2023, then spiked by 130.61% to $113,000 in 2024.